Loading…
Lobbying Spend
—
Filings
18
Firms Hired
1
Active Period
2013–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2017 · fourth_quarter · Firm: THE D MAJOR GROUP
Promote health savings account reforms, including first-dollar coverage of chronic disease medicines as well as services offered at retail health clinics. Advocate for a lower domestic corporate tax rate as proposed under HR 1, the "Tax Cuts and Jobs Act."
Client expense: — · Firm income: $30,000
Matched citations: HR 1
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
2017 · fourth_quarter · Firm: THE D MAJOR GROUP
Advocate on behalf of pharmaceutical benefit management practices impacted by direct and indirect remuneration and point of sale rebates related to the Medicare Part D prescription drug benefit program. In addition, monitor Medicare payment issues concerning home infusion, the Medicare Extenders package and S. 870, the Chronic Care Act of 2017.
Client expense: — · Firm income: $30,000
Matched citations: S. 870
American Health Care Act of 2017
2017 · third_quarter · Firm: THE D MAJOR GROUP
Monitor policy matters related to H.R. 1628, the American Health Care Act of 2017; and the Better Care Reconciliation Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 1628
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: THE D MAJOR GROUP
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 2430
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 934
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2017 · third_quarter · Firm: THE D MAJOR GROUP
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 974
American Health Care Act of 2017
2017 · second_quarter · Firm: THE D MAJOR GROUP
Monitor policy matters related to H.R. 1628, the American Health Care Act of 2017; and the Better Care Reconciliation Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 1628
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: THE D MAJOR GROUP
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 2430
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 934
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2017 · second_quarter · Firm: THE D MAJOR GROUP
Engage with policymakers on proposals related to pharmaceutical pricing, including issues related to H.R. 2430, the FDA Reauthorization Act of 2017; S. 934, the Food and Drug Administration Reauthorization Act; and S. 974, the CREATES Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 974
American Health Care Act of 2017
2017 · first_quarter · Firm: THE D MAJOR GROUP
Monitor policy matters related to H.R. 1628, the American Health Care Act of 2017.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 1628
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act; H.R. 34, The 21st Century Cures Act; and H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 244
Issues concerning the administration of the Medicare Part D prescription drug benefit. In addition, home infusion payment matters as contained in H.R. 34, The 21st Century Cures Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 34
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act; H.R. 34, The 21st Century Cures Act; and H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 34
Increasing Competition in Pharmaceuticals Act
2016 · fourth_quarter · Firm: THE D MAJOR GROUP
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act; H.R. 34, The 21st Century Cures Act; and H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 2615
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $34,500
Matched citations: H.R. 244
Improving Health Information Technology Act
2016 · third_quarter · Firm: THE D MAJOR GROUP
Issues concerning health information technology innovation, including S. 2511, The Improving Health IT Act. Also, advocate for maintenance of quality home health payments related to S. 275, The Home Infusion Site of Care Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 2511
Increasing Competition in Pharmaceuticals Act
2016 · third_quarter · Firm: THE D MAJOR GROUP
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 2615
Medicare Home Infusion Site of Care Act of 2015
2016 · third_quarter · Firm: THE D MAJOR GROUP
Issues concerning health information technology innovation, including S. 2511, The Improving Health IT Act. Also, advocate for maintenance of quality home health payments related to S. 275, The Home Infusion Site of Care Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 275
Comprehensive Addiction and Recovery Act of 2016
2016 · third_quarter · Firm: THE D MAJOR GROUP
Issues concerning the administration of the Medicare Part D prescription drug benefit. In addition, drug abuse prevention matters related to Part D including S. 524, The Comprehensive Addiction & Recovery Act.
Client expense: — · Firm income: $34,500
Matched citations: S. 524
A bill to reauthorize and amend the National Sea Grant College Program Act, and for other purposes.
2016 · third_quarter · Firm: THE D MAJOR GROUP
Monitor issues concerning labeling requirements for certain biotech food products, including S. 764.
Client expense: — · Firm income: $34,500
Matched citations: S. 764
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 244
Improving Health Information Technology Act
2016 · second_quarter · Firm: THE D MAJOR GROUP
Issues concerning health information technology innovation, including S. 2511, The Improving Health IT Act. Also, advocate for maintenance of quality home health payments related to S. 275, The Home Infusion Site of Care Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 2511
Increasing Competition in Pharmaceuticals Act
2016 · second_quarter · Firm: THE D MAJOR GROUP
Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 2615
Medicare Home Infusion Site of Care Act of 2015
2016 · second_quarter · Firm: THE D MAJOR GROUP
Issues concerning health information technology innovation, including S. 2511, The Improving Health IT Act. Also, advocate for maintenance of quality home health payments related to S. 275, The Home Infusion Site of Care Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 275
Source: Senate LDA